Literature DB >> 24673811

Prognostic evaluation of breast cancer patients with evident bone marrow metastasis.

Lutfiye Demir1, Murat Akyol, Sadi Bener, Kadriye Bahriye Payzin, Cigdem Erten, Isil Somali, Alper Can, Ahmet Dirican, Vedat Bayoglu, Yuksel Kucukzeybek, Ahmet Alacacioglu, Aylin Orgen Calli, Mustafa Oktay Tarhan.   

Abstract

In this study, we aimed to evaluate the clinicopathologic characteristics and prognosis of breast cancer (BC) patients with symptomatic bone marrow metastasis (BMM). Fifty-four BC patients, including patients with and without BMM, were evaluated retrospectively. In particular, the clinicopathologic features and survival of the patients with BMM (n = 27) were assessed and compared with the patients without BMM. All of the patients with BMM also had osseous metastases, and bone was the first site for distant recurrence in the majority of patients in the study group. Anemia was the most frequent symptom at presentation. The median time to BMM was 36.1 months (range 1.6-70.5 months, 95% CI). HER2(+) patients developed BMM earlier than HER2(-) patients (3.2 versus 38.3 months, 95% CI; p = 0.05). Patients with advanced disease at the time of initial BC diagnosis developed BMM earlier than patients with early disease (p = 0.04). Time to development of BMM was significantly shorter in tumors with perinodal infiltration (p = 0.001) and multicentric focus (p = 0.025). Median survival time after the diagnosis of apparent BMM was 6.43 months. Survival after BMM diagnosis in patients with grade III tumors was significantly shorter than in patients with grade I-II tumors (1.43 versus 5.36 months, 95% CI; p < 0.001). Systemic therapy after BMM diagnosis significantly prolonged survival (17.3 versus 0.93 months, 95% CI; p < 0.001). Hormone receptor-positive, high-grade, advanced-stage tumors at the time of initial BC diagnosis were more common in patients with BMM. Invasive lobular histology was also more frequent in patients with BMM. In conclusion, the presence of hormone receptor-positive, multicentric, grade III, advanced-stage tumors may be important risk factors for the development of evident BMM in BC patients. Systemic single-agent chemotherapy can prolong survival in these patients. However, multicenter analyses are required to verify these findings.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  bone marrow metastasis; breast cancer; prognosis; survival

Mesh:

Year:  2014        PMID: 24673811     DOI: 10.1111/tbj.12264

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  6 in total

1.  Clinicopathological characteristics of disseminated carcinomatosis of the bone marrow in breast cancer patients.

Authors:  Yoshiaki Shinden; Keishi Sugimachi; Fumiaki Tanaka; Kenji Fujiyoshi; Yuko Kijima; Shoji Natsugoe; Koshi Mimori
Journal:  Mol Clin Oncol       Date:  2017-11-15

2.  Bone Marrow Carcinomatosis in a Stage IV Breast Cancer Patient Treated by Letrozole as First-Line Endocrine Therapy.

Authors:  Tsuyoshi Nakagawa; Kumiko Hayashi; Ayumi Ogawa; Goshi Oda; Iichiro Onishi; Masahide Yamamoto; Mio Mori; Tomoyuki Fujioka; Toshiaki Ishikawa; Kentaro Okamoto; Hiroyuki Uetake
Journal:  Case Rep Oncol       Date:  2022-04-22

3.  Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy.

Authors:  Takeshi Yamaguchi; Mariko Masumoto; Urara Sakurai; Minoru Nakane
Journal:  Case Rep Oncol       Date:  2020-02-24

4.  Skeletal Metastasis as Detected by 18F-FDG PET with Negative CT of the PET/CT: Frequency and Impact on Cancer Staging and/or Management.

Authors:  Fatma Ahmed; Razi Muzaffar; Hermina Fernandes; Yifan Tu; Batool Albalooshi; Medhat M Osman
Journal:  Front Oncol       Date:  2016-10-10       Impact factor: 6.244

5.  Bone Marrow Metastasis Is an Early Stage of Bone Metastasis in Breast Cancer Detected Clinically by F18-FDG-PET/CT Imaging.

Authors:  Kusai M Al-Muqbel
Journal:  Biomed Res Int       Date:  2017-08-13       Impact factor: 3.411

6.  Diffuse Bone Marrow Metastasis as the Initial Presentation of an Occult Breast Cancer.

Authors:  Frank S Fan; Chung-Fan Yang; Yi-Fen Wang
Journal:  Case Rep Oncol Med       Date:  2018-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.